Annals of the Rheumatic Diseases

Article	Citations
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update	528
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study	493
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry	483
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update	333
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort	272
Microenvironment in subchondral bone: predominant regulator for the treatment of osteoarthritis	221
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis	219
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial	206
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity	205
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis	205
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression	200
METTL3-mediated m 6 A modification of ATG7 regulates autophagy-GATA4 axis to promote cellular senescence and osteoarthritis progression	177
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome	176
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update	174
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease	172
Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study	171
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement	171
Axial spondyloarthritis	162
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases	162
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2	158
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib	156
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis	153
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update	153
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2	152
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study	151

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases	150
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial	150
2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis	148
2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis	147
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases	137
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry	132
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry	131
Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients	128
EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis	121
Large-scale meta-analysis across East Asian and European populations updated genetic architecture and variant-driven biology of rheumatoid arthritis, identifying 11 novel susceptibility loci	117
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response	113
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis	111
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis	110
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial	109
Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus	109
Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets	108
Anti-inflammatory therapy for COVID-19 infection: the case for colchicine	104
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular	98
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases	96
EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update	96
2023 ACR/EULAR antiphospholipid syndrome classification criteria	96
PathogenicUBA1variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis	95
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study	95
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3	92
2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases	91
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database	90
Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial	89
Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong	89
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial	87
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial	86
Mechanical overloading promotes chondrocyte senescence and osteoarthritis development through downregulating FBXW7	84
Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations	83
2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis	82
Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’	81
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases	77
2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases	74
Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial	72
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study	72
Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative	71
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial	71
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update	71
Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis	70
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial	70
Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells	69
Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases	69
Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City	68
Osteoarthritis endotype discovery via clustering of biochemical marker data	68
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration	66
‘SMASH’ recommendations for standardised microscopic arthritis scoring of histological sections from inflammatory arthritis animal models	66
circPDE4B prevents articular cartilage degeneration and promotes repair by acting as a scaffold for RIC8A and MID1	66

Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic	65
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial	65
Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort	64
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial	64
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases	63
Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis	63
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial	62
Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles	62
Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts	61
Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus	60
Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan	60
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort	60
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials	59
Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis	59
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis	59
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study	59
SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists	58
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised,	57
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study	57
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis	57
BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus	57
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndr	56
Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-α-mediated ERK1/2 and JAK-STAT1 pathways	56
Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial	56
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance	55
Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial	55
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis	55
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis	54
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial	54
Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis	53
EULAR recommendations for intra-articular therapies	53
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis	51
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance	51
Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese	50
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases	50
Efficacy and safety of emapalumab in macrophage activation syndrome	50
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years	49
Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis	49
Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries	49
Whole gut virome analysis of 476 Japanese revealed a link between phage and autoimmune disease	48
Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial	48
Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial	48
Choose wisely: imaging for diagnosis of axial spondyloarthritis	48
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials	48
Onset of rheumatoid arthritis after COVID-19: coincidence or connected?	48
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study	48
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis	47
Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study	47
Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series	47
Efficacy of COVID-19 vaccines in patients taking immunosuppressants	47
Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register	46
Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial	46
Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis	46
Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α	46
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial	46
EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs	46
Correction:EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update	45
Mechanosensitive TRPV4 is required for crystal-induced inflammation	44
From real-world electronic health record data to real-world results using artificial intelligence	44
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis	43
Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis	43
Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases	42
European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance	42
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial	42
AB0606 IMPACT OF ABDOMINAL AORTIC CALCIFICATION AND SERUM CREATININE-TO-CYSTATIN C RATIO TO BONE FRAGILITY FRACTURE	42
EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis	41
Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spon	41
14-3-3 epsilon is an intracellular component of TNFR2 receptor complex and its activation protects against osteoarthritis	41
Neutrophil extracellular trap-associated carbamylation and histones trigger osteoclast formation in rheumatoid arthritis	40
Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines	40
Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients	40
Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren’s syndrome shared megakaryocyte expansion in peripheral blood	39
Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting	39
Targeting the IL-6–Yap–Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis	39
Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series	39
Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis	39
Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases	39
Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset	39
The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS	39
Single cell and spatial transcriptomics in human tendon disease indicate dysregulated immune homeostasis	38

JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications	38
Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go?	38
No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?	37
ChatGPT: when artificial intelligence replaces the rheumatologist in medical writing	36
Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome	36
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica	36
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial	36
Genome-wide association study identifies RNF123 locus as associated with chronic widespread musculoskeletal pain	36
Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis	36
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration	35
Time to reconsider what Global Burden of Disease studies really tell us about low back pain	35
Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease	35
Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus	35
Does biologic therapy impact the development of PsA among patients with psoriasis?	35
Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial	35
Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers	34
SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease	34
Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases	34
Genomic repertoires linked with pathogenic potency of arthritogenicPrevotella copriisolated from the gut of patients with rheumatoid arthritis	34
The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)	34
American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision	34
MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group	33
Variants in urate transporters, ADH1B, GCKR and MEPE genes associate with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Cauc	33
Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases	33
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial	33
Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis	33
Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease	33
Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity	33
Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-γ hyper-responsiveness and risk for macrophage activation syn	33
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of	32
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials	32
EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs)	32
Multi-trait and cross-population genome-wide association studies across autoimmune and allergic diseases identify shared and distinct genetic component	32
Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study	32
Linking chondrocyte and synovial transcriptional profile to clinical phenotype in osteoarthritis	32
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme	32
Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis	31
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19	31
Tissue physiology revolving around the clock: circadian rhythms as exemplified by the intervertebral disc	31
Novel autoantibodies identified in ACPA-negative rheumatoid arthritis	31
TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis	31
SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases	31
Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades	31
Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?	31
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases	31
Stage-specific roles of microbial dysbiosis and metabolic disorders in rheumatoid arthritis	31
AB0222 COMPARISON OF SELF-INJECTION DEVICES FOR ADMINISTERING ANTI-TUMOR NECROSIS FACTOR AGENTS USING THE ORIGINAL QUESTIONNAIRE IN PATIENTS WITH RHEUMATOID ARTHRITIS	31
Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases	30
AB0546 5 YEARS FOLLOW-UP OF PSORIATIC ARTHRITIS PATIENTS TREATED ACCORDING TREAT-TO-TARGET STRATEGY. PRELIMINARY RESULTS	30
Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors	30
Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes entheseal new bone formation through activation of Hippo signalling in ankylosing spondylitis	30
BNT162b2 mRNA COVID-19 vaccine and booster in patients with autoimmune rheumatic diseases: a national cohort study	30
New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis	29
Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming	29
Taxonomy of fibroblasts and progenitors in the synovial joint at single-cell resolution	29
Streptococcus species enriched in the oral cavity of patients with RA are a source of peptidoglycan-polysaccharide polymers that can induce arthritis in mice	29
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis	29
IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors	29
Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider	29
Exercise and education versus saline injections for knee osteoarthritis: a randomised controlled equivalence trial	29
Novel self-amplificatory loop between T cells and tenocytes as a driver of chronicity in tendon disease	29
Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey	29
Local steroid activation is a critical mediator of the anti-inflammatory actions of therapeutic glucocorticoids	28
Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids	28
PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes	28
Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study	28
Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes	28
2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice	27
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study	27
Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave	27
Instrument selection for the ASAS core outcome set for axial spondyloarthritis	27
Response to: Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update" by Ramiroet al	27
Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis	27
Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis	27
The provisional OMERACT ultrasonography score for giant cell arteritis	27
2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19	26
SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy	26
Non-surgical and surgical treatments for rotator cuff disease: a pragmatic randomised clinical trial with 2-year follow-up after initial rehabilitation	26
EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021	26
Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study	26
Microglia activation in the presence of intact blood–brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus	26
Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?	25
Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes	25
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception coh	25
From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift?	25
New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE	25
Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis	25
Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients: the PreCARA study	25
Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus	24
Vitamin K antagonist anticoagulant usage is associated with increased incidence and progression of osteoarthritis	24
Arg206Cys substitution in DNASE1L3 causes a defect in DNASE1L3 protein secretion that confers risk of systemic lupus erythematosus	24
EULAR study group on ‘MHC-I-opathy’: identifying disease-overarching mechanisms across disciplines and borders	24
Immune cell multiomics analysis reveals contribution of oxidative phosphorylation to B-cell functions and organ damage of lupus	24
Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area	24
Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy	24